GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Short-Term Debt

GRFS (Grifols) Short-Term Debt : $0 Mil (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grifols Short-Term Debt?

Grifols's Short-Term Debt for the quarter that ended in Sep. 2024 was $0 Mil.

Grifols's quarterly Short-Term Debt increased from Dec. 2023 ($862 Mil) to Jun. 2024 ($2,765 Mil) but then declined from Jun. 2024 ($2,765 Mil) to Sep. 2024 ($0 Mil).

Grifols's annual Short-Term Debt increased from Dec. 2022 ($613 Mil) to Dec. 2023 ($862 Mil) but then declined from Dec. 2023 ($862 Mil) to Dec. 2024 ($541 Mil).

Grifols Short-Term Debt Historical Data

The historical data trend for Grifols's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Short-Term Debt Chart

Grifols Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.90 2,650.41 613.26 862.39 540.54

Grifols Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 862.39 2,765.18 - 540.54

Grifols Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Grifols Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Grifols's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Short-Term Debt
Comparable Companies
XMAD:ALM XMAD:FAE XMAD:RJF XMAD:LAB LLY OCSE:NOVO B JNJ ABBV XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
GIKLY:USA GIFOF:USA GIFLF:USA GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain OZTA:Germany GRF:Austria
Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.